Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
140.56
-0.87 (-0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sarepta Therapeutics
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Where Sarepta Therapeutics Stands With Analysts
July 29, 2022
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Apple, Amazon And Some Other Big Stocks Recording Gains On Friday
July 29, 2022
Getty Images Holdings, Inc. (NYSE: GETY) shares jumped 106.7% to $21.69 after nearly 99.4% of shares were redeemed by CCNB shareholders.
Via
Benzinga
Exxon Mobil (XOM) Stock Pops on Record Profits
July 29, 2022
Exxon Mobil (XOM) stock is rising on Friday following the release of its earnings report for the second quarter of the year.
Via
InvestorPlace
CENN Stock Alert: Cenntro Invests in E-Cargo Designer
July 29, 2022
Cenntro (CENN) stock is on the move Friday as investors react to news of the electric vehicle (EV) company acquiring a stake in Antric.
Via
InvestorPlace
Sarepta (SRPT) Stock Gains on FDA News
July 29, 2022
Sarepta Therapeutics (SRPT) stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment.
Via
InvestorPlace
Where Sarepta Therapeutics Stands With Analysts
June 24, 2022
Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Expert Ratings for Sarepta Therapeutics
May 19, 2022
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Via
Benzinga
Sarepta Intents To Seek Accelerated Approval For Gene Therapy Candidate
July 29, 2022
Sarepta Therapeutics (NASDAQ: SRPT) announced its intention to submit Biologics License Application (BLA) seeking accelerated approval for SRP-9001 to treat ambulant individuals with Duchenne muscular...
Via
Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
July 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 20, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew
July 12, 2022
Via
Benzinga
Sarepta Therapeutics: Q1 Earnings Insights
May 04, 2022
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Scheduled For March 1, 2022
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 07, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Investors Search for Clues in Economic Data, Recession Signals
July 06, 2022
Stocks are extending this morning's quiet losses, as investors continue to keep an eye on signs of an oncoming recession.
Via
Talk Markets
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
July 06, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
June 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study
June 23, 2022
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 17, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Sarepta Therapeutics's Earnings: A Preview
May 03, 2022
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating
April 07, 2022
On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier.
Via
Investor's Business Daily
Tough Slogging Ahead for Investors, Diversification is Important
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
Where Sarepta Therapeutics Stands With Analysts
March 02, 2022
Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
Sarepta Therapeutics: Q4 Earnings Insights
March 01, 2022
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
Sarepta Therapeutics's Earnings Outlook
February 28, 2022
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.